Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by M Córdoba
Raltegravir: A Potent and Safe Integrase Inhibitor With a Favourable Impact on Cardiovascular and Liver Profile
Journal of the International AIDS Society
Environmental
Public Health
Infectious Diseases
Occupational Health
Related publications
Early Onset of Autoimmune Disease by the Retroviral Integrase Inhibitor Raltegravir
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
Mutations Associated With Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor in Vitro
Antimicrobial Agents and Chemotherapy
Infectious Diseases
Pharmacology
Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir
Clinical Pharmacokinetics
Pharmacology
Evidence That Raltegravir (Isentress, Merck), a Retroviral Integrase Inhibitor Is Effective Against Recurrent Human Herpes Simplex Virus Infection Associated With NK-cell Deficiency
Pediatrics & Therapeutics
A Long-Acting Formulation of the Integrase Inhibitor Raltegravir Protects Humanized BLT Mice From Repeated High-Dose Vaginal HIV Challenges
Journal of Antimicrobial Chemotherapy
Infectious Diseases
Microbiology
Pharmacology
In Vitro Antiviral Profile of Ruzasvir: A Potent and Pan-Genotype Inhibitor of HCV NS5A
Antimicrobial Agents and Chemotherapy
Infectious Diseases
Pharmacology
PHA-739358, a Potent Inhibitor of Aurora Kinases With a Selective Target Inhibition Profile Relevant to Cancer
Molecular Cancer Therapeutics
Cancer Research
Oncology
Figure 1: FDA Approved Integrase Strand Transfer Inhibitors INSTIs: Raltegravir, Elvitegravir and Dolutegravir.
Circulating Irisin Concentrations Are Associated With a Favourable Lipid Profile in the General Population
PLoS ONE
Multidisciplinary
